Fig. 10: Colocalization of ST2⁺ T_reg cells and CD8 T cells is disrupted by engineered anti-ST2 antibody in the splenic leukemic niche of epigenetically mutated immunocompetent myeloid DNMT3A/FLT3^ITD mice.

A, B Representative sizes and weights of spleens and livers from DNMT3A/FLT3^ITD transplanted mice after the 10th administration of control Ab or anti-ST2 Ab (n = 5 in each group). C Representative plots and frequencies of spleen CD3⁺CD8⁺ T cells and frequencies of spleen CD3⁺CD4⁺ T cells following the 10th administration of control Ab or anti-ST2 Ab (n = 5 in each group). D Frequencies of spleen myeloid-derived suppressor cells/ monocytes (CD11b⁺Gr1^intF4/80⁺) and spleen neutrophils (Gr1⁺CD11b⁺) following the 10th administration of control Ab or anti-ST2 Ab (n = 5 in each group). E Representative confocal images showing DAPI (blue), anti-CD4 (yellow), anti-FoxP3 (green), anti-ST2 (red), anti-CD8a (cyan), and merged immunofluorescence staining in the spleens of DNMT3A/FLT3^ITD AML mice treated with either control antibody (Control-Ab) or anti-ST2 antibody (Anti-ST2-Ab). In the spleens of Anti-ST2-Ab-treated AML mice, ST2⁺ T_reg cells (CD4⁺FoxP3⁺ST2⁺) are nearly absent, while the number of CD8 T cells is significantly increased compared to the control-Ab-treated group. The shortest distance between ST2⁺ T_reg cells (insert in merged image, highlighted with a yellow arrow) and CD8 T cells (insert in merged image, highlighted with a red arrow) was quantified using Imaris (Elmo) software. Data are mean ± s.e.m. (n = 5 in each experiment). A two-sided unpaired t-test was used. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.